Viking Therapeutics, Inc. (VKTX)
31.98
-0.15
(-0.47%)
USD |
NASDAQ |
Sep 11, 16:00
31.84
-0.14
(-0.44%)
After-Hours: 07:46
Viking Therapeutics Enterprise Value : 3.233B for Sept. 11, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 11, 2026 | 3.233B |
| September 10, 2026 | 3.250B |
| September 09, 2026 | 3.317B |
| September 08, 2026 | 3.431B |
| September 04, 2026 | 3.570B |
| September 03, 2026 | 3.466B |
| September 02, 2026 | 3.410B |
| September 01, 2026 | 3.430B |
| August 31, 2026 | 3.326B |
| August 28, 2026 | 3.254B |
| August 27, 2026 | 3.452B |
| August 26, 2026 | 3.513B |
| August 25, 2026 | 3.488B |
| August 24, 2026 | 3.379B |
| August 21, 2026 | 3.456B |
| August 20, 2026 | 3.511B |
| August 19, 2026 | 3.700B |
| August 18, 2026 | 3.395B |
| August 17, 2026 | 3.425B |
| August 14, 2026 | 3.374B |
| August 13, 2026 | 3.345B |
| August 12, 2026 | 3.471B |
| August 11, 2026 | 3.445B |
| August 10, 2026 | 3.520B |
| August 07, 2026 | 3.499B |
| Date | Value |
|---|---|
| August 06, 2026 | 3.387B |
| August 05, 2026 | 3.411B |
| August 04, 2026 | 3.345B |
| August 03, 2026 | 3.306B |
| July 31, 2026 | 3.205B |
| July 30, 2026 | 3.365B |
| July 29, 2026 | 3.402B |
| July 28, 2026 | 3.452B |
| July 27, 2026 | 3.570B |
| July 24, 2026 | 3.561B |
| July 23, 2026 | 3.631B |
| July 22, 2026 | 3.855B |
| July 21, 2026 | 3.929B |
| July 20, 2026 | 3.746B |
| July 17, 2026 | 3.828B |
| July 16, 2026 | 3.745B |
| July 15, 2026 | 3.913B |
| July 14, 2026 | 3.932B |
| July 13, 2026 | 3.949B |
| July 10, 2026 | 4.036B |
| July 09, 2026 | 4.302B |
| July 08, 2026 | 4.164B |
| July 07, 2026 | 4.417B |
| July 06, 2026 | 4.018B |
| July 02, 2026 | 3.870B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Vertex Pharmaceuticals, Inc. | 124.70B |
| Eli Lilly & Co. | 1.096T |
| Regeneron Pharmaceuticals, Inc. | 75.51B |
| Ironwood Pharmaceuticals, Inc. | 991.92M |
| Xencor, Inc. | 1.528B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -128.02M |
| Total Expenses (Quarterly) | 128.02M |
| EPS Diluted (Quarterly) | -1.101 |
| Earnings Yield | -14.58% |
| Normalized Earnings Yield | -14.58 |